CrossRef Cited-by Linking Search Results

This Article:

has been cited by the following articles in journals that are participating in CrossRef Cited-by Linking:

  • Immunohistochemical analysis of the mammalian target of rapamycin signalling pathway in extramammary Paget’s disease
    S. Chen, T. Nakahara, H. Uchi, S. Takeuchi, M. Takahara, M. Kido, L. Dugu, Y. Tu, Y. Moroi, and M. Furue
    British Journal of Dermatology (2009) 161 :357
  • Evaluation of the mTOR pathway in ocular (uvea and conjunctiva) melanoma
    Helena Pópulo, Paula Soares, Ana Sofia Rocha, Paula Silva, and José Manuel Lopes
    Melanoma Research (2010) 20 :107
  • PTEN hamartoma tumor syndromes
    Gideon M Blumenthal and Phillip A Dennis
    European Journal of Human Genetics (2008) 16 :1289
  • Approaches to target the genome and its epigenome in cancer
    Nadine Chapman-Rothe and Robert Brown
    Future Medicinal Chemistry (2009) 1 :1481
  • Metastatic melanoma: Chemotherapy
    Emilio Bajetta, Michele Del Vecchio, Chantal Bernard-Marty, Milena Vitali, Roberto Buzzoni, Olivier Rixe, Paola Nova, Stefania Aglione, Sophie Taillibert, and David Khayat
    Seminars in Oncology (2002) 29 :427
  • New strategies to overcome resistance to mammalian target of rapamycin inhibitors in breast cancer
    Cecile Vicier, Maria V. Dieci, and Fabrice Andre
    Current Opinion in Oncology (2013) 25 :587
  • Efficacy of a rapamycin analog (CCI-779) and IFN-? in tuberous sclerosis mouse models
    Laifong Lee, Paul Sudentas, Brian Donohue, Kirsten Asrican, Aelaf Worku, Victoria Walker, Yanping Sun, Karl Schmidt, Mitchell S. Albert, Nisreen El-Hashemite, Alan S. Lader, Hiroaki Onda, Hongbing Zhang, David J. Kwiatkowski, and Sandra L. Dabora
    Genes, Chromosomes and Cancer (2005) 42 :213
  • Temsirolimus for advanced renal cell carcinoma
    Lothar Bergmann, Luise Maute, and Michael Guschmann
    Expert Review of Anticancer Therapy (2014) 14 :9
  • Rapamycin Inhibits Proliferation of Estrogen-Receptor-Positive Breast Cancer Cells
    Sharon B. Chang, Penelope Miron, Alexander Miron, and J. Dirk Iglehart
    Journal of Surgical Research (2007) 138 :37
  • Discovery of a Novel Class of Highly Potent, Selective, ATP-Competitive, and Orally Bioavailable Inhibitors of the Mammalian Target of Rapamycin (mTOR)
    Craig S. Takeuchi, Byung Gyu Kim, Charles M. Blazey, Sunghoon Ma, Henry W. B. Johnson, Neel K. Anand, Arlyn Arcalas, Tae Gon Baik, Chris A. Buhr, Jonah Cannoy, Sergey Epshteyn, Anagha Joshi, Katherine Lara, Matthew S. Lee, Longcheng Wang, James W. Leahy, John M. Nuss, Naing Aay, Ron Aoyama, Paul Foster, Jae Lee, Isabelle Lehoux, Narsimha Munagala, Arthur Plonowski, Sharmila Rajan, John Woolfrey, Kyoko Yamaguchi, Peter Lamb, and Nicole Miller
    Journal of Medicinal Chemistry (2013) 56 :2218
  • Stability of ready-to-use temsirolimus infusion solution (100mg/L) in polypropylene containers under different storage conditions
    S. Poujol, F. Bressolle, I. Solassol, and F. Pinguet
    Annales Pharmaceutiques Françaises (2012) 70 :155
  • TOR (target of rapamycin) as an anti-cancer target
    Guilhem Bousquet, Chantal Dreyer, Sandrine Faivre, and Eric Raymond
    Drug Discovery Today: Therapeutic Strategies (2007) 4 :211
  • Discovery of 2-arylthieno[3,2-d]pyrimidines containing 8-oxa-3-azabi-cyclo[3.2.1]octane in the 4-position as potent inhibitors of mTOR with selectivity over PI3K
    Jeroen C. Verheijen, Ker Yu, Lourdes Toral-Barza, Irwin Hollander, and Arie Zask
    Bioorganic & Medicinal Chemistry Letters (2010) 20 :375
  • Targeting the mTOR signaling network in cancer
    Gary G. Chiang and Robert T. Abraham
    Trends in Molecular Medicine (2007) 13 :433
  • Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer
    S Chan
    British Journal of Cancer (2004) 91 :1420
  • Elastin-based protein polymer nanoparticles carrying drug at both corona and core suppress tumor growth in vivo
    Pu Shi, Suhaas Aluri, Yi-An Lin, Mihir Shah, Maria Edman, Jugal Dhandhukia, Honggang Cui, and J. Andrew MacKay
    Journal of Controlled Release (2013) 171 :330
  • Rapamycin and tumor growth: mechanisms behind its anticancer activity
    Gudrun E. Koehl, Hans J. Schlitt, and Edward K. Geissler
    Transplantation Reviews (2005) 19 :20
  • mTOR inhibitors in breast cancer: A systematic review
    Flora Zagouri, Theodoros N. Sergentanis, Dimosthenis Chrysikos, Martin Filipits, and Rupert Bartsch
    Gynecologic Oncology (2012) 127 :662
  • The complexity of PTEN: mutation, marker and potential target for therapeutic intervention
    Linda S Steelman, Fred E Bertrand, and James A McCubrey
    Expert Opinion on Therapeutic Targets (2004) 8 :537
  • mTOR inhibitors in the treatment of cancer
    Angelica Fasolo and Cristiana Sessa
    Expert Opinion on Investigational Drugs (2008) 17 :1717
  • Pharmacodynamic evaluation of temsirolimus in patients with newly diagnosed advanced-stage head and neck squamous cell carcinoma
    Oleksandr Ekshyyan, Glenn M. Mills, Timothy Lian, Nazanin Amirghahari, Xiaohua Rong, Mary Lowery-Nordberg, Fleurette Abreo, Diana M. Veillon, Gloria Caldito, Lisa Speicher, Jonathan Glass, and Cherie-Ann O. Nathan
    Head & Neck (2010) 32 :1619
  • Néphrotoxicité du sirolimus : données cliniques et expérimentales
    Nicolas Pallet, Eric Thervet, Christophe Legendre, and Dany Anglicheau
    Néphrologie & Thérapeutique (2006) 2 :183
  • Curcumin inhibits the mammalian target of rapamycin-mediated signaling pathways in cancer cells
    Christopher S. Beevers, Fengjun Li, Lei Liu, and Shile Huang
    International Journal of Cancer (2006) 119 :757
  • Early endometrial carcinoma: clinicopathology, hormonal aspects, molecular genetics, diagnosis, and treatment
    Tanri Shiozawa and Ikuo Konishi
    International Journal of Clinical Oncology (2006) 11 :13
  • Aromatase inhibitors: Combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance
    Stephen R.D. Johnston, Lesley-Ann Martin, Julia Head, Ian Smith, and Mitch Dowsett
    The Journal of Steroid Biochemistry and Molecular Biology (2005) 95 :173
  • Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies
    Alicia M Viloria-Petit and Robert S Kerbel
    International Journal of Radiation Oncology*Biology*Physics (2004) 58 :914
  • HIF at the crossroads between ischemia and carcinogenesis
    Stefan A.M. Paul, Jonathan W. Simons, and Nicola J. Mabjeesh
    Journal of Cellular Physiology (2004) 200 :20
  • Femara® and the future: tailoring treatment and combination therapies with Femara
    Matthew Ellis and Cynthia Ma
    Breast Cancer Research and Treatment (2007) 105 :105
  • Inhibition of bladder tumour growth by sirolimus in an experimental carcinogenesis model
    Belmiro Parada, Flávio Reis, Arnaldo Figueiredo, Pedro Nunes, Edite Teixeira-Lemos, Patrícia Garrido, José Sereno, Rui Pinto, Maria F.X. Cunha, Paula Neto, Paulo Santos, Isabel Velada, Alfredo Mota, and Frederico Teixeira
    BJU International (2011) 107 :135
  • The association between Akt activation and resistance to hormone therapy in metastatic breast cancer
    Eriko Tokunaga, Akemi Kataoka, Yasue Kimura, Eiji Oki, Kojiro Mashino, Kojiro Nishida, Tadashi Koga, Masaru Morita, Yoshihiro Kakeji, Hideo Baba, Shinji Ohno, and Yoshihiko Maehara
    European Journal of Cancer (2006) 42 :629
  • Her2-positive breast cancer: Herceptin and beyond
    Windy Dean-Colomb and Francisco J. Esteva
    European Journal of Cancer (2008) 44 :2806
  • Anti-lymphangiogenic properties of mTOR inhibitors in head and neck squamous cell carcinoma experimental models
    Oleksandr Ekshyyan, Tara N Moore-Medlin, Matthew C Raley, Kunal Sonavane, Xiaohua Rong, Michael A Brodt, Fleurette Abreo, Jonathan Alexander, and Cherie-Ann O Nathan
    BMC Cancer (2013) 13 :320
  • Novel therapies for patients with chronic myeloid leukemia
    Francis J Giles, Hagop Kantarjian, and Jorge Cortes
    Expert Review of Anticancer Therapy (2004) 4 :271
  • mTOR Inhibitors in Advanced Renal Cell Carcinoma
    Martin H. Voss, Ana M. Molina, and Robert J. Motzer
    Hematology/Oncology Clinics of North America (2011) 25 :835
  • Sulforaphane inhibits growth of phenotypically different breast cancer cells
    Anna Pawlik, Aleksandra Wiczk, Angelika Kaczyńska, Jędrzej Antosiewicz, and Anna Herman-Antosiewicz
    European Journal of Nutrition (2013) 52 :1949
  • High-throughput ectopic expression screen for tamoxifen resistance identifies an atypical kinase that blocks autophagy
    Laura Gonzalez-Malerva, Jaehong Park, Lihua Zou, Yanhui Hu, Zahra Moradpour, Joseph Pearlberg, Jacqueline Sawyer, Hallam Stevens, Ed Harlow, and Joshua LaBaer
    Proceedings of the National Academy of Sciences (2011) 108 :2058
  • mTOR and cancer: reason for dancing at the crossroads?
    George V Thomas
    Current Opinion in Genetics & Development (2006) 16 :78
  • Effect of Combination Treatment of Rapamycin and Isoflavones on mTOR Pathway in Human Glioblastoma (U87) Cells
    Shilpa Puli, Aditi Jain, James C. K. Lai, and Alok Bhushan
    Neurochemical Research (2010) 35 :986
  • Combination of a rapamycin analog (CCI-779) and interferon-γ is more effective than single agents in treating a mouse model of tuberous sclerosis complex
    Laifong Lee, Paul Sudentas, and Sandra L. Dabora
    Genes, Chromosomes and Cancer (2006) 45 :933
  • Inhibition of Either Phosphatidylinositol 3-kinase/Akt or the Mitogen/Extracellular-regulated Kinase, MEK/ERK, Signaling Pathways Suppress Growth of Breast Cancer Cell Lines, but MEK/ERK Signaling is Critical for Cell Survival
    Maureen O. Ripple, Sahana Kalmadi, and Alan Eastman
    Breast Cancer Research and Treatment (2005) 93 :177
  • Rapamycin: An anti-cancer immunosuppressant?
    Brian K. Law
    Critical Reviews in Oncology/Hematology (2005) 56 :47
  • Differentiating mTOR inhibitors in renal cell carcinoma
    Sumanta K. Pal and David I. Quinn
    Cancer Treatment Reviews (2013) 39 :709
  • Differential sensitivities of trastuzumab (Herceptin®)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors
    Carmel T. Chan, Marianne Z. Metz, and Susan E. Kane
    Breast Cancer Research and Treatment (2005) 91 :187
  • 2003 Highlights from: 26th Annual San Antonio Breast Cancer Symposium San Antonio, Texas, December 2003
    G. Kesava Reddy, Preeta Tyagi, Vinay K. Jain, and Joyce O'Shaughnessy
    Clinical Breast Cancer (2004) 5 :22
  • Breast Cancer Chemoprevention: Old and New Approaches
    Massimiliano Cazzaniga and Bernardo Bonanni
    Journal of Biomedicine and Biotechnology (2012) 2012 :1
  • Exploring mammalian target of rapamycin (mTOR) inhibition for treatment of mantle cell lymphoma and other hematologic malignancies
    Bertrand Coiffier and Vincent Ribrag
    Leukemia & Lymphoma (2009) 50 :1916
  • Targeting translation: eIF4E as an emerging anticancer drug target
    Chunwan Lu, Levi Makala, Daqing Wu, and Yafei Cai
    Expert Reviews in Molecular Medicine (2016) 18 :
  • Clinical strategies for rationale combinations of aromatase inhibitors with novel therapies for breast cancer
    Stephen R.D. Johnston, Lesley-Ann Martin, Alex Leary, Julia Head, and Mitch Dowsett
    The Journal of Steroid Biochemistry and Molecular Biology (2007) 106 :180
  • Mammalian Target of Rapamycin Inhibitors in Combination with Letrozole in Breast Cancer
    Philippe Chollet, Catherine Abrial, Olivier Tacca, Marie-Ange Mouret-Reynier, Marianne Leheurteur, Xavier Durando, and Hervé Curé
    Clinical Breast Cancer (2006) 7 :336
  • Synergistic anti-tumor effects of RAD001 with MEK inhibitors in neuroendocrine tumors: A potential mechanism of therapeutic limitation of mTOR inhibitor
    Shinya Iida, Yasuhiro Miki, Katsuhiko Ono, Jun-ichi Akahira, Yasuhiro Nakamura, Takashi Suzuki, and Hironobu Sasano
    Molecular and Cellular Endocrinology (2012) 350 :99
  • Urban Endocrine Disruptors Targeting Breast Cancer Proteins
    Diana Montes-Grajales, Gonçalo J. L. Bernardes, and Jesus Olivero-Verbel
    Chemical Research in Toxicology (2016) :
  • Are we missing the mTOR target in breast cancer?
    Stephen R. D. Johnston
    Breast Cancer Research and Treatment (2011) 128 :607
  • Phorbol 12-myristate 13-acetate and serum synergize to promote rapamycin-insensitive cell proliferation via protein kinase C-eta
    P M Martin, S E Aeder, C A Chrestensen, T W Sturgill, and I M Hussaini
    Oncogene (2007) 26 :407
  • Treatment of Her2-Positive Breast Cancer: What’s on the Horizon
    Windy Dean-Colomb and Francisco J. Esteva
    Current Breast Cancer Reports (2010) 2 :42
  • Everolimus for renal cell carcinoma: predictive factors for response and future directions
    Guru Sonpavde and Thomas E. Hutson
    Medical Oncology (2009) 26 :46
  • Differential Role of Rapamycin and Torin/KU63794 in Inflammatory Response of 264.7 RAW Macrophages Stimulated by CA-MRSA
    Rebekah K. H. Shappley and Thomas Spentzas
    International Journal of Inflammation (2014) 2014 :1
  • New Therapeutic strategies for soft tissue sarcomas
    Margaret von Mehren
    Current Treatment Options in Oncology (2003) 4 :441
  • Dihydroartemisinin inhibits the mammalian target of rapamycin-mediated signaling pathways in tumor cells
    Yoshinobu Odaka, Baoshan Xu, Yan Luo, Tao Shen, Chaowei Shang, Yang Wu, Hongyu Zhou, and Shile Huang
    Carcinogenesis (2014) 35 :192
  • Recovery and Purification of Rapamycin from the Culture Broth of Mtcc 5681
    Polavarapu Baby Rani, Battula Suneel Kumar, A.K.S. Bhujanga Rao, S. Sreenivasr, and Mangamoori Lakshmi Narasu
    Pakistan Journal of Biological Sciences (2013) 16 :219
  • Identification of p27/KIP1 expression level as a candidate biomarker of response to rapalogs therapy in human cancer
    Guang Chen, Na Yang, Xiang Wang, Si-Yuan Zheng, Yi Chen, Lin-Jiang Tong, Yi-Xue Li, Ling-Hua Meng, and Jian Ding
    Journal of Molecular Medicine (2010) 88 :941
  • Hormonal Resistance in Breast Cancer: Evolving Treatment Strategies
    Mustafa Khasraw, Sandra L. Harvey, and Richard Bell
    Current Breast Cancer Reports (2012) 4 :66
  • Everolimus in hormone receptor–positive advanced breast cancer: Targeting receptor-based mechanisms of resistance
    Mikhail I. Shtivelband
    The Breast (2013) 22 :405
  • A Phase 1 Clinical Study of Temsirolimus (CCI-779) in Japanese Patients with Advanced Solid Tumors
    Y. Fujisaka, Y. Yamada, N. Yamamoto, A. Horiike, and T. Tamura
    Japanese Journal of Clinical Oncology (2010) 40 :732
  • Screening of immunophilin ligands by quantitative analysis of neurofilament expression and neurite outgrowth in cultured neurons and cells
    Danni Liu, H. Beal McIlvain, Myles Fennell, John Dunlop, Andrew Wood, Margaret M. Zaleska, Edmund I. Graziani, and Kevin Pong
    Journal of Neuroscience Methods (2007) 163 :310
  • A Hypoxia-Controlled Cap-Dependent to Cap-Independent Translation Switch in Breast Cancer
    Steve Braunstein, Ksenia Karpisheva, Carolina Pola, Judith Goldberg, Tsivia Hochman, Herman Yee, Joan Cangiarella, Rezina Arju, Silvia C. Formenti, and Robert J. Schneider
    Molecular Cell (2007) 28 :501
  • Analysis of PTEN and HIF-1α and correlation with efficacy in patients with advanced renal cell carcinoma treated with temsirolimus versus interferon-α
    Robert A. Figlin, Paul de Souza, David McDermott, Janice P. Dutcher, Anna Berkenblit, Alexandra Thiele, Mizue Krygowski, Andrew Strahs, Jay Feingold, Joseph Boni, and Gary Hudes
    Cancer (2009) 115 :3651
  • Bioinformatics-based discovery and characterization of an AKT-selective inhibitor 9-chloro-2-methylellipticinium acetate (CMEP) in breast cancer cells
    Manchao Zhang, Xueliang Fang, Hongpeng Liu, Ribo Guo, Xiaojin Wu, Bihua Li, Feng Zhu, Yan Ling, Brian N. Griffith, Shaomeng Wang, and Dajun Yang
    Cancer Letters (2007) 252 :244
  • Temsirolimus for the treatment of mantle cell lymphoma
    Georg Hess
    Expert Review of Hematology (2009) 2 :631
  • Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer
    Jan C. Buckner, Bahram Forouzesh, Charles Erlichman, Manuel Hidalgo, Joseph P. Boni, Gary Dukart, Anna Berkenblit, and Eric K. Rowinsky
    Investigational New Drugs (2010) 28 :334
  • Triple-negative breast cancer: Molecular features, pathogenesis, treatment and current lines of research
    Ana Bosch, Pilar Eroles, Rosa Zaragoza, Juan R. Viña, and Ana Lluch
    Cancer Treatment Reviews (2010) 36 :206
  • Mutasynthesis of Rapamycin Analogues through the Manipulation of a Gene Governing Starter Unit Biosynthesis
    Matthew A. Gregory, Hrvoje Petkovic, Rachel E. Lill, Steven J. Moss, Barrie Wilkinson, Sabine Gaisser, Peter F. Leadlay, and Rose M. Sheridan
    Angewandte Chemie (2005) 117 :4835
  • Successes and failures: an overview of lessons learnt in the creation of targeted therapy strategies for breast cancer
    S. R. D. Johnston
    Breast Cancer Online (2007) 10 :
  • Everolimus: a new hope for patients with breast cancer
    Mehmet A.N. Sendur, Nurullah Zengin, Sercan Aksoy, and Kadri Altundag
    Current Medical Research and Opinion (2014) 30 :75
  • Translationsansätze in der Tumorstammzellforschung
    C. Mozet, G. Wichmann, and A. Dietz
    HNO (2011) 59 :859
  • Evaluating Temsirolimus Activity in Multiple Tumors: A Review of Clinical Trials
    Janet E. Dancey, Rafael Curiel, and Joseph Purvis
    Seminars in Oncology (2009) 36 :S46
  • Rapamycin inhibits cell proliferation in type I and type II endometrial carcinomas: A search for biomarkers of sensitivity to treatment
    Victoria L. Bae-Jump, Chunxiao Zhou, John F. Boggess, Young E. Whang, Lisa Barroilhet, and Paola A. Gehrig
    Gynecologic Oncology (2010) 119 :579
  • The mTOR pathway inhibitor RAD001 (everolimus) is highly efficacious in tamoxifen-sensitive and -resistant breast cancer xenografts
    Diana Behrens, Anne E. Lykkesfeldt, and Iduna Fichtner
    Targeted Oncology (2007) 2 :135
  • Ten years of sirolimus therapy in orthotopic liver transplant recipients
    G.W Neff, M Montalbano, and A.G Tzakis
    Transplantation Proceedings (2003) 35 :S209
  • Temisorlimus in the treatment of advanced renal cell carcinoma
    Bernard J. Escudier
    Oncology Reviews (2007) 1 :73
  • Molecular insights into endocrine resistance
    Stephen R.D. Johnston
    European Journal of Cancer Supplements (2005) 3 :225
  • Molecular-targeted therapies: Lessons from years of clinical development
    Daniela D. Rosa, Gustavo Ismael, Lissandra Dal Lago, and Ahmad Awada
    Cancer Treatment Reviews (2008) 34 :61
  • Pyrazolopyrimidines as highly potent and selective, ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR): Optimization of the 1-substituent
    Kevin J. Curran, Jeroen C. Verheijen, Joshua Kaplan, David J. Richard, Lourdes Toral-Barza, Irwin Hollander, Judy Lucas, Semiramis Ayral-Kaloustian, Ker Yu, and Arie Zask
    Bioorganic & Medicinal Chemistry Letters (2010) 20 :1440
  • Optimal treatment strategies in postmenopausal women with hormone-receptor-positive and HER2-negative metastatic breast cancer
    Joseph Gligorov and Jean-Pierre Lotz
    Breast Cancer Research and Treatment (2008) 112 :53
  • Effectiveness and molecular interactions of the clinically active mTORC1 inhibitor everolimus in combination with tamoxifen or letrozole in vitro and in vivo
    Lesley-Ann Martin, Sunil Pancholi, Ian Farmer, Stephanie Guest, Ricardo Ribas, Marion T Weigel, Allan M Thornhill, Zara Ghazoui, Roger A'Hern, Dean B Evans, Heidi A Lane, Stephen R Johnston, and Mitch Dowsett
    Breast Cancer Research (2012) 14 :R132
  • Effects of Rapamycin on Cell Apoptosis in MCF-7 Human Breast Cancer Cells
    Tengku Ahmad Damitri Al-Astani Tengku Din, Azman Seeni, Wirdatul-Nur Mohd Khairi, Shaharum Shamsuddin, and Hasnan Jaafar
    Asian Pacific Journal of Cancer Prevention (2015) 15 :10659
  • Targeting mTOR-mediated survival signals in anticancer therapeutic strategies
    David A Foster
    Expert Review of Anticancer Therapy (2004) 4 :691
  • Novel purine and pyrazolo[3,4-d]pyrimidine inhibitors of PI3 kinase-α: Hit to lead studies
    Adam M. Gilbert, Pawel Nowak, Natasja Brooijmans, Matthew G. Bursavich, Christoph Dehnhardt, Efren Delos Santos, Larry R. Feldberg, Irwin Hollander, Stephen Kim, Sabrina Lombardi, Kaapjoo Park, Aranapakam M. Venkatesan, and Robert Mallon
    Bioorganic & Medicinal Chemistry Letters (2010) 20 :636
  • Novel Gemini-vitamin D3 analog inhibits tumor cell growth and modulates the Akt/mTOR signaling pathway
    James O’Kelly, Milan Uskokovic, Nathan Lemp, Jay Vadgama, and H. Phillip Koeffler
    The Journal of Steroid Biochemistry and Molecular Biology (2006) 100 :107
  • Nouvelles approches pharmacologiques de traitement des cancers
    Bruno Buecher and Hervé M. Blottière
    Gastroentérologie Clinique et Biologique (2004) 28 :167
  • Conversion to sirolimus: A useful strategy for recalcitrant cutaneous viral warts in liver transplant recipient
    Sébastien Dharancy, Benoît Catteau, Laurent Mortier, Emmanuel Boleslawski, Nicole Declerck, Valérie Canva, Frédéric Piette, Philippe Mathurin, and François René Pruvot
    Liver Transplantation (2006) 12 :1883
  • Mutant Type Glutathione S-transferase Theta 1 Gene Homologue to mTOR in Myelodysplastic Syndrome: Possible Clinical Application of Rapamycin
    Yasuhiro Maeda, Terufumi Yamaguchi, Satomi Ueda, Koki Matsuo, Yasuyoshi Morita, Yoshito Naiki, Hajime Miyazato, Takahiro Shimada, Jun-ichi Miyatake, Mitsuhiro Matsuda, and Akihisa Kanamaru
    Leukemia & Lymphoma (2003) 44 :1179
  • The novel mTOR inhibitor CCI-779 (temsirolimus) induces antiproliferative effects through inhibition of mTOR in Bel-7402 liver cancer cells
    Shuyu Li, Yan Liang, Manlin Wu, Xiaojing Wang, Haixia Fu, Yuhao Chen, and Zhigang Wang
    Cancer Cell International (2013) 13 :30
  • Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(ε-caprolactone) micelles of rapamycin
    Jaime A. Yáñez, M. Laird Forrest, Yusuke Ohgami, Glen S. Kwon, and Neal M. Davies
    Cancer Chemotherapy and Pharmacology (2007) 61 :133
  • Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus
    I. Duran, L.L. Siu, A.M. Oza, T.-B. Chung, J. Sturgeon, C.A. Townsley, G.R. Pond, L. Seymour, and M. Niroumand
    European Journal of Cancer (2006) 42 :1875
  • Activation of PI3K/Akt signaling and hormone resistance in breast cancer
    Eriko Tokunaga, Yasue Kimura, Kojiro Mashino, Eiji Oki, Akemi Kataoka, Shinji Ohno, Masaru Morita, Yoshihiro Kakeji, Hideo Baba, and Yoshihiko Maehara
    Breast Cancer (2006) 13 :137
  • Current and future systemic treatments for renal cell carcinoma
    Rosalie Fisher, Martin Gore, and James Larkin
    Seminars in Cancer Biology (2013) 23 :38
  • Targeting downstream effectors of epidermal growth factor receptor/HER2 in breast cancer with either farnesyltransferase inhibitors or mTOR antagonists
    International Journal of Gynecological Cancer (2006) 16 :543
  • The emerging role of the PI3-K-Akt pathway in prostate cancer progression
    L Li, M M Ittmann, G Ayala, M-J Tsai, R J Amato, T M Wheeler, B J Miles, D Kadmon, and T C Thompson
    Prostate Cancer and Prostatic Diseases (2005) 8 :108
  • Mammalian Target of Rapamycin: Discovery of Rapamycin Reveals a Signaling Pathway Important for Normal and Cancer Cell Growth
    James J. Gibbons, Robert T. Abraham, and Ker Yu
    Seminars in Oncology (2009) 36 :S3
  • Effects of a combined treatment with mTOR inhibitor RAD001 and tamoxifen in vitro on growth and apoptosis of human cancer cells
    Oliver Treeck, Birgit Wackwitz, Ulrike Haus, and Olaf Ortmann
    Gynecologic Oncology (2006) 102 :292
  • Overexpression of S6 Kinase 1 in Brain Tumours Is Associated with Induction of Hypoxia-Responsive Genes and Predicts Patients' Survival
    Heba M.S. Ismail
    Journal of Oncology (2012) 2012 :1
  • Novel systemic therapies for breast cancer
    Soo Lo and Stephen R.D. Johnston
    Surgical Oncology (2003) 12 :277
  • Current Status and Challenges Associated with Targeting mTOR for Cancer Therapy
    Ryan J.O. Dowling, Michael Pollak, and Nahum Sonenberg
    BioDrugs (2009) 23 :77
  • Phase II trial of temsirolimus in patients with metastatic breast cancer
    Gini F. Fleming, Cynthia X. Ma, Dezheng Huo, Husain Sattar, Maria Tretiakova, L. Lin, Olwen M. Hahn, F. O. Olopade, R. Nanda, Philip C. Hoffman, M. J. Naughton, Timothy Pluard, Suzanne D. Conzen, and Matthew J. Ellis
    Breast Cancer Research and Treatment (2012) 136 :355
  • Delivering preventive, predictive and personalised cancer medicine for renal cell carcinoma: the challenge of tumour heterogeneity
    Rosalie Fisher, James Larkin, and Charles Swanton
    EPMA Journal (2012) 3 :
  • Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors
    Catherine Delbaldo, Sébastien Albert, Chantal Dreyer, Marie-Paule Sablin, Maria Serova, Eric Raymond, and Sandrine Faivre
    Targeted Oncology (2011) 6 :119
  • HER2-Positive Breast Cancer: From Trastuzumab to Innovatory Anti-HER2 Strategies
    Nicolas Whenham, Véronique D'Hondt, and Martine J. Piccart
    Clinical Breast Cancer (2008) 8 :38
  • Mammalian target of rapamycin (mTOR) inhibitors
    Janice P. Dutcher
    Current Oncology Reports (2004) 6 :111
  • Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation
    A. Hollebecque, T. Decaens, E. Boleslawski, P. Mathurin, C. Duvoux, F.-R. Pruvot, and S. Dharancy
    Gastroentérologie Clinique et Biologique (2009) 33 :361
  • Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: Possible role for thrombosis
    Sherry A. Weppler, Mechthild Krause, Agnieszka Zyromska, Philippe Lambin, Michael Baumann, and Bradly G. Wouters
    Radiotherapy and Oncology (2007) 82 :96
  • Activation of the PI3K/Akt pathway and chemotherapeutic resistance
    Kip A West, S Sianna Castillo, and Phillip A Dennis
    Drug Resistance Updates (2002) 5 :234
  • Novel benzofuran-3-one indole inhibitors of PI3 kinase-α and the mammalian target of rapamycin: Hit to lead studies
    Matthew G. Bursavich, Natasja Brooijmans, Lawrence Feldberg, Irwin Hollander, Stephen Kim, Sabrina Lombardi, Kaapjoo Park, Robert Mallon, and Adam M. Gilbert
    Bioorganic & Medicinal Chemistry Letters (2010) 20 :2586
  • Temsirolimus
    Drugs in R & D (2004) 5 :363
  • In vitro release of the mTOR inhibitor rapamycin from poly(ethylene glycol)-b-poly(ε-caprolactone) micelles
    M. Laird Forrest, Chee-Youb Won, A. Waseem Malick, and Glen S. Kwon
    Journal of Controlled Release (2006) 110 :370
  • Targeting mammalian target of rapamycin (mTOR) for health and diseases
    Chi Kwan Tsang, Haiyan Qi, Leroy F. Liu, and X.F. Steven Zheng
    Drug Discovery Today (2007) 12 :112
  • The mTOR Signalling Pathway in Cancer and the Potential mTOR Inhibitory Activities of Natural Phytochemicals
    Heng Kean Tan, Ahmed Ismail Hassan Moad, and Mei Lan Tan
    Asian Pacific Journal of Cancer Prevention (2014) 15 :6463
  • Glutamine deprivation stimulates mTOR-JNK-dependent chemokine secretion
    Naval P. Shanware, Kevin Bray, Christina H. Eng, Fang Wang, Maximillian Follettie, Jeremy Myers, Valeria R. Fantin, and Robert T. Abraham
    Nature Communications (2014) 5 :4900
  • The mTOR Pathway in Breast Cancer
    Nancy E. Hynes and Anne Boulay
    Journal of Mammary Gland Biology and Neoplasia (2006) 11 :53
  • Mechanisms of translational deregulation in human tumors and therapeutic intervention strategies
    B Bilanges and D Stokoe
    Oncogene (2007) 26 :5973
  • Small Molecule Signal Transduction Inhibitors for the Treatment of Solid Tumors
    Alexandra Leary and Stephen R. D. Johnston
    Cancer Investigation (2007) 25 :347
  • Can We Circumvent Resistance To ErbB2-Targeted Agents By Targeting Novel Pathways?
    Mark Pegram
    Clinical Breast Cancer (2008) 8 :S121
  • The influence of co-solvents on the stability and bioavailability of rapamycin formulated in self-microemulsifying drug delivery systems
    Minghui Sun, Luqin Si, Xuezhen Zhai, Zhaoze Fan, Yiming Ma, Rui Zhang, and Xiangliang Yang
    Drug Development and Industrial Pharmacy (2011) 37 :986
  • l-Type amino acid transporter 1 inhibitors inhibit tumor cell growth
    Koji Oda, Noriko Hosoda, Hiroshi Endo, Kunio Saito, Kenji Tsujihara, Michio Yamamura, Takeshi Sakata, Naohiko Anzai, Michael F. Wempe, Yoshikatsu Kanai, and Hitoshi Endou
    Cancer Science (2010) 101 :173
  • Resistance to epidermal growth factor receptor-targeted therapy
    Floriana Morgillo and Ho-Young Lee
    Drug Resistance Updates (2005) 8 :298
  • The Relationship Between Estrogen/Progesterone Receptor and Expression of mTOR/pAkt Proteins and the Analysis of Prognosis in Breast Cancer
    Sun Wook Han, Moon Soo Lee, Sung Yong Kim, Gil Ho Kang, Zi Sun Kim, Cheol Wan Lim, Ji Hyun Lee, Hyun Ju Lee, Mee-Hye Oh, and Min Hyuk Lee
    Journal of Breast Disease (2013) 1 :8
  • Local delivery of rapamycin: a toxicity and efficacy study in an experimental malignant glioma model in rats
    B. Tyler, S. Wadsworth, V. Recinos, V. Mehta, A. Vellimana, K. Li, J. Rosenblatt, H. Do, G. L. Gallia, I.-M. Siu, R. T. Wicks, M. A. Rudek, M. Zhao, and H. Brem
    Neuro-Oncology (2011) 13 :700
  • The rapamycin analog CCI-779 is a potent inhibitor of pancreatic cancer cell proliferation
    Takayuki Asano, Yixin Yao, Jijiang Zhu, Donghui Li, James L. Abbruzzese, and Shrikanth A. Reddy
    Biochemical and Biophysical Research Communications (2005) 331 :295
  • Activation of the mTOR signaling pathway in breast cancer and its correlation with the clinicopathologic variables
    Woo Chul Noh, Yang Hee Kim, Min Suk Kim, Jae Soo Koh, Hyun-Ah Kim, Nan Mo Moon, and Nam-Sun Paik
    Breast Cancer Research and Treatment (2008) 110 :477
  • mTOR pathway activation in cutaneous melanoma is associated with poorer prognosis characteristics
    H. Pópulo, P. Soares, A. Faustino, A. S. Rocha, P. Silva, F. Azevedo, and J. M. Lopes
    Pigment Cell & Melanoma Research (2011) 24 :254
  • PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor
    Aranapakam M. Venkatesan, Zecheng Chen, Osvaldo Dos Santos, Christoph Dehnhardt, Efren Delos Santos, Semiramis Ayral-Kaloustian, Robert Mallon, Irwin Hollander, Larry Feldberg, Judy Lucas, Ker Yu, Inder Chaudhary, and Tarek S. Mansour
    Bioorganic & Medicinal Chemistry Letters (2010) 20 :5869
  • Rapamycin sensitizes Akt inhibition in malignant human breast epithelial cells
    Jie Zheng, Alice Hudder, Kim Zukowski, and Raymond F. Novak
    Cancer Letters (2010) 296 :74
  • Breast cancer tissue slices as a model for evaluation of response to rapamycin
    Stana Helena Giorgi Grosso, Maria Lucia Hirata Katayama, Rosimeire Aparecida Roela, Suely Nonogaki, Fernando Augusto Soares, Helena Brentani, Leandro Lima, Maria Aparecida Azevedo Koike Folgueira, Angela Flávia Logullo Waitzberg, Fátima Solange Pasini, João Carlos Guedes Sampaio Góes, and M. Mitzi Brentani
    Cell and Tissue Research (2013) 352 :671
  • Novel targeted agents for the treatment of advanced breast cancer
    Máximo de la Vega, Enrique Díaz-Cantón, and Ricardo H Alvarez
    Future Medicinal Chemistry (2012) 4 :893
  • mTOR signaling in glioblastoma: lessons learned from bench to bedside
    D. Akhavan, T. F. Cloughesy, and P. S. Mischel
    Neuro-Oncology (2010) 12 :882
  • Highlights From: the 41st Annual Meeting of the American Society of Clinical Oncology; Orlando, FL May 2005
    G. Kesava Reddy, Preeta Tyagi, Susan Peck, Tara Beers Gibson, and Joyce A. O'Shaughnessy
    Clinical Breast Cancer (2005) 6 :191
  • Progression and treatment of HER2-positive breast cancer
    April Davoli, Barbara A. Hocevar, and Thomas L. Brown
    Cancer Chemotherapy and Pharmacology (2010) 65 :611
  • Natural products to drugs: natural product derived compounds in clinical trials
    Mark S. Butler
    Natural Product Reports (2005) 22 :162
  • Focus on breast cancer
    Jose Baselga and Larry Norton
    Cancer Cell (2002) 1 :319
  • The role of S6K1 in ER-positive breast cancer
    Marina K. Holz
    Cell Cycle (2012) 11 :3159
  • Mutasynthesis of Rapamycin Analogues through the Manipulation of a Gene Governing Starter Unit Biosynthesis
    Matthew A. Gregory, Hrvoje Petkovic, Rachel E. Lill, Steven J. Moss, Barrie Wilkinson, Sabine Gaisser, Peter F. Leadlay, and Rose M. Sheridan
    Angewandte Chemie International Edition (2005) 44 :4757
  • Clinical development of mammalian target of rapamycin inhibitors
    Janet E Dancey
    Hematology/Oncology Clinics of North America (2002) 16 :1101
  • The role of VEGF in triple-negative breast cancer: where do we go from here?
    S. F. Dent
    Annals of Oncology (2009) 20 :1615
  • Endocrine therapy and other targeted therapies for metastatic breast cancer
    Syed A Hussain, Daniel H Palmer, Sarah Moon, and Daniel W Rea
    Expert Review of Anticancer Therapy (2004) 4 :1179
  • The mTOR Signalling Pathway in Human Cancer
    Helena Pópulo, José Manuel Lopes, and Paula Soares
    International Journal of Molecular Sciences (2012) 13 :1886
  • Targeting the PI3K/AKT/mTOR and Raf/MEK/ERK pathways in the treatment of breast cancer
    Kamal S. Saini, Sherene Loi, Evandro de Azambuja, Otto Metzger-Filho, Monika Lamba Saini, Michail Ignatiadis, Janet E. Dancey, and Martine J. Piccart-Gebhart
    Cancer Treatment Reviews (2013) 39 :935
  • Hypoxia-mediated drug resistance: Novel insights on the functional interaction of HIFs and cell death pathways
    Nadine Rohwer and Thorsten Cramer
    Drug Resistance Updates (2011) 14 :191
  • Reduced Expression of Tocopherol-Associated Protein (TAP/Sec14L2) in Human Breast Cancer
    Xi Wang, Jing Ni, Chen-Long Hsu, Sharlin Johnykutty, Ping Tang, Yuan-Soon Ho, Chia-Hwa Lee, and Shuyuang Yeh
    Cancer Investigation (2009) 27 :971
  • Phosphorylation of ribosomal p70 S6 kinase and rapamycin sensitivity in human colorectal cancer
    Hiroaki Nozawa, Toshiaki Watanabe, and Hirokazu Nagawa
    Cancer Letters (2007) 251 :105
  • Combination of rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt activation and potentiates mTOR blockade in breast cancer cells
    Matthew M. Roforth and Chalet Tan
    Anti-Cancer Drugs (2008) 19 :681
  • 2-Arylureidophenyl-4-(3-oxa-8-azabicyclo[3.2.1]octan-8-yl)triazines as highly potent and selective ATP competitive mTOR inhibitors: Optimization of human microsomal stability
    Jeroen C. Verheijen, David J. Richard, Kevin Curran, Joshua Kaplan, Ker Yu, and Arie Zask
    Bioorganic & Medicinal Chemistry Letters (2010) 20 :2648
  • Dissecting the role of mTOR: Lessons from mTOR inhibitors
    Ryan J.O. Dowling, Ivan Topisirovic, Bruno D. Fonseca, and Nahum Sonenberg
    Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics (2010) 1804 :433
  • Proteins, drug targets and the mechanisms they control: the simple truth about complex networks
    Robyn P. Araujo, Lance A. Liotta, and Emanuel F. Petricoin
    Nature Reviews Drug Discovery (2007) 6 :871
  • Potential Role of Mammalian Target of Rapamycin Inhibitors in Breast Cancer Therapy
    Funda Meric-Bernstam and Francisco J. Esteva
    Clinical Breast Cancer (2005) 6 :357
  • Discovery of 3,6-dihydro-2H-pyran as a morpholine replacement in 6-aryl-1H-pyrazolo[3,4-d]pyrimidines and 2-arylthieno[3,2-d]pyrimidines: ATP-competitive inhibitors of the mammalian target of rapamycin (mTOR)
    Joshua Kaplan, Jeroen C. Verheijen, Natasja Brooijmans, Lourdes Toral-Barza, Irwin Hollander, Ker Yu, and Arie Zask
    Bioorganic & Medicinal Chemistry Letters (2010) 20 :640
  • Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines
    Bénédicte Martin, Julien Edeline, Jean-Jacques Patard, Emmanuel Oger, Florence Jouan, Gaëlla Boulanger, Sélim Zerrouki, Cécile Vigneau, and Nathalie Rioux-Leclercq
    Journal of Cancer Research and Clinical Oncology (2012) 138 :907
  • Evidence that low-dose, long-term genistein treatment inhibits oestradiol-stimulated growth in MCF-7 cells by down-regulation of the PI3-kinase/Akt signalling pathway
    Nitharnie Anastasius, Staci Boston, Michael Lacey, Nicola Storing, and Saffron Ann Whitehead
    The Journal of Steroid Biochemistry and Molecular Biology (2009) 116 :50
  • Triple-Negative Breast Cancer
    Sally Greenberg and Hope S. Rugo
    The Cancer Journal (2010) 16 :33
  • Recent advances in the molecular genetics of primary gliomas
    Gaspar J. Kitange, Kristen L. Templeton, and Robert B. Jenkins
    Current Opinion in Oncology (2003) 15 :197
  • Targeting triple-negative breast cancer: optimising therapeutic outcomes
    K. Gelmon, R. Dent, J. R. Mackey, K. Laing, D. McLeod, and S. Verma
    Annals of Oncology (2012) 23 :2223
  • C6 ceramide dramatically enhances docetaxel-induced growth inhibition and apoptosis in cultured breast cancer cells: A mechanism study
    Lan Yang, Li-yun Zheng, Ye Tian, Zhi-qing Zhang, Wan-li Dong, Xu-fen Wang, Xiao-ying Zhang, and Cong Cao
    Experimental Cell Research (2015) 332 :47
  • Phase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: A Gynecologic Oncology Group study
    Kian Behbakht, Michael W. Sill, Kathleen M. Darcy, Stephen C. Rubin, Robert S. Mannel, Steven Waggoner, Russell J. Schilder, Kathy Q. Cai, Andrew K. Godwin, and R. Katherine Alpaugh
    Gynecologic Oncology (2011) 123 :19
  • Emerging Targeted Therapies for Breast Cancer
    Monica Arnedos and Andrew D. Seidman
    Hematology/Oncology Clinics of North America (2007) 21 :321
  • Rapamycin inhibits hTERT telomerase mRNA expression, independent of cell cycle arrest
    Victoria L. Bae-Jump, Chunxiao Zhou, Paola A. Gehrig, Young E. Whang, and John F. Boggess
    Gynecologic Oncology (2006) 100 :487
  • Expression of the Mammalian Target of Rapamycin Pathway Markers in Lung Adenocarcinoma and Squamous Cell Carcinoma
    Hyun-Soo Kim, Gou Young Kim, Sung-Jig Lim, and Youn Wha Kim
    Pathobiology (2012) 79 :84
  • Targeting Insulin and Insulin-Like Growth Factor Signaling in Breast Cancer
    Yuzhe Yang and Douglas Yee
    Journal of Mammary Gland Biology and Neoplasia (2012) 17 :251
  • Downstream intracellular effectors of epidermal growth factor receptor as targets for anticancer therapy
    Amalia Milano, Vincenzo De Rosa, Rosario Vincenzo Iaffaioli, and Francesco Caponigro
    Expert Opinion on Therapeutic Targets (2007) 11 :771
  • mTOR pathway inhibition in renal cell carcinoma
    Alvaro Pinto Marín, Andrés Redondo Sánchez, Enrique Espinosa Arranz, Pilar Zamora Auñón, Beatriz Castelo Fernández, and Manuel González Barón
    Urologic Oncology: Seminars and Original Investigations (2012) 30 :356
  • Emerging drugs for hepatocellular carcinoma
    Lewis R Roberts and Gregory J Gores
    Expert Opinion on Emerging Drugs (2006) 11 :469
  • Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCC
    Robert A Figlin
    Nature Clinical Practice Oncology (2008) 5 :601
  • Coexistence of the loss of heterozygosity at the PTEN locus and HER2 overexpression enhances the Akt activity thus leading to a negative progesterone receptor expression in breast carcinoma
    Eriko Tokunaga, Eiji Oki, Yasue Kimura, Takeharu Yamanaka, Akinori Egashira, Kojiro Nishida, Tadashi Koga, Masaru Morita, Yoshihiro Kakeji, and Yoshihiko Maehara
    Breast Cancer Research and Treatment (2007) 101 :249
  • Mammalian target of rapamycin inhibition as therapy for hematologic malignancies
    Amit Panwalkar, Srdan Verstovsek, and Francis J. Giles
    Cancer (2004) 100 :657
  • Effects of rapamycin on cell proliferation and phosphorylation of mTOR and p70S6K in HepG2 and HepG2 cells overexpressing constitutively active Akt/PKB
    Shailly Varma and Ramji L. Khandelwal
    Biochimica et Biophysica Acta (BBA) - General Subjects (2007) 1770 :71
  • PTEN deficiency is a common defect in juvenile myelomonocytic leukemia
    Yunying Lucy Liu, Robert P. Castleberry, and Peter D. Emanuel
    Leukemia Research (2009) 33 :671
  • Investigating mammalian target of rapamycin inhibitors for their anticancer properties
    Piotr Smolewski
    Expert Opinion on Investigational Drugs (2006) 15 :1201
  • Syntheses and antiproliferative evaluation of oxyphenisatin derivatives
    Muhammed K. Uddin, Serge G. Reignier, Tom Coulter, Christian Montalbetti, Charlotta Grånäs, Steven Butcher, Christian Krog-Jensen, and Jakob Felding
    Bioorganic & Medicinal Chemistry Letters (2007) 17 :2854
  • Potentiating effects of RAD001 (Everolimus) on vincristine therapy in childhood acute lymphoblastic leukemia
    R. Crazzolara, A. Cisterne, M. Thien, J. Hewson, R. Baraz, K. F. Bradstock, and L. J. Bendall
    Blood (2009) 113 :3297
  • PTEN hamartomatous tumor syndromes (PHTS): Rare syndromes with great relevance to common cancers and targeted drug development
    Jaclyn LoPiccolo, Marc S. Ballas, and Phillip A. Dennis
    Critical Reviews in Oncology/Hematology (2007) 63 :203
  • Targeting LKB1 signaling in cancer
    S.E. Korsse, M.P. Peppelenbosch, and W. van Veelen
    Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2013) 1835 :194
  • Dosing of rapamycin is critical to achieve an optimal antiangiogenic effect against cancer
    Markus Guba, Gudrun E. Koehl, Evelyn Neppl, Axel Doenecke, Markus Steinbauer, Hans J. Schlitt, Karl-Walter Jauch, and Edward K. Geissler
    Transplant International (2005) 18 :89
  • Mammalian Target of Rapamycin: A New Molecular Target for Breast Cancer
    Monica M. Mita, Alain Mita, and Eric K. Rowinsky
    Clinical Breast Cancer (2003) 4 :126
  • Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
    Gary Hudes, Michael Carducci, Piotr Tomczak, Janice Dutcher, Robert Figlin, Anil Kapoor, Elzbieta Staroslawska, Jeffrey Sosman, David McDermott, István Bodrogi, Zoran Kovacevic, Vladimir Lesovoy, Ingo G.H. Schmidt-Wolf, Olga Barbarash, Erhan Gokmen, Timothy O'Toole, Stephanie Lustgarten, Laurence Moore, and Robert J. Motzer
    New England Journal of Medicine (2007) 356 :2271
  • Use of mTOR inhibitors in the treatment of malignancies
    Nisha A Mohindra, Francis J Giles, and Leonidas C Platanias
    Expert Opinion on Pharmacotherapy (2014) 15 :979
  • Decreased levels of hypoxic cells in gefitinib treated ER+ HER-2 overexpressing MCF-7 breast cancer tumors are associated with hyperactivation of the mTOR pathway: therapeutic implications for combination therapy with rapamycin
    Wieslawa H. Dragowska, Maïté Verreault, Donald T. T. Yapp, Corinna Warburton, Lincoln Edwards, Euan C. Ramsay, Lynsey A. Huxham, Andrew I. Minchinton, Karen Gelmon, and Marcel B. Bally
    Breast Cancer Research and Treatment (2007) 106 :319
  • Targeting Endocrine Resistance: Is There a Role for mTOR Inhibition?
    Amna Sheri, Lesley-Ann Martin, and Stephen Johnston
    Clinical Breast Cancer (2010) 10 :S79
  • Mechanisms of resistance to rapamycins
    Shile Huang and Peter J. Houghton
    Drug Resistance Updates (2001) 4 :378